Viral anti‐inflammatory serpin reduces immuno‐coagulopathic pathology in SARS‐CoV‐2 mouse models of infection

Abstract SARS‐CoV‐2 acute respiratory distress syndrome (ARDS) induces uncontrolled lung inflammation and coagulopathy with high mortality. Anti‐viral drugs and monoclonal antibodies reduce early COVID‐19 severity, but treatments for late‐stage immuno‐thrombotic syndromes and long COVID are limited....

Full description

Saved in:

Bibliographic Details
Main Authors:	Liqiang Zhang, Yize Henry Li, Karen Kibler, Simona Kraberger, Arvind Varsani, Julie Turk, Nora Elmadbouly, Emily Aliskevich, Laurel Spaccarelli, Bereket Estifanos, Junior Enow, Isabela Rivabem Zanetti, Nicholas Saldevar, Efrem Lim, Jessika Schlievert, Kyle Browder, Anjali Wilson, Fernando Arcos Juan, Aubrey Pinteric, Aman Garg, Henna Monder, Rohan Saju, Savanah Gisriel, Bertram Jacobs, Timothy L Karr, Esther Borges Florsheim, Vivek Kumar, John Wallen, Masmudur Rahman, Grant McFadden, Brenda G Hogue, Alexandra R Lucas
Format:	Article
Language:	English
Published:	Springer Nature 2023-08-01
Series:	EMBO Molecular Medicine
Subjects:	complement inflammation SARS‐CoV‐2 serpin uPAR
Online Access:	https://doi.org/10.15252/emmm.202317376
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Viral anti‐inflammatory serpin reduces immuno‐coagulopathic pathology in SARS‐CoV‐2 mouse models of infection

Similar Items